亚宝药业(600351.SH)：GLX002获得药物临床试验批准通知书

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), announced that its wholly-owned subsidiary, Beijing Yabao Biological Pharmaceutical Co., Ltd., has received the clinical trial approval notice for GLX002 from the National Medical Products Administration of China [1] Group 1: Product Information - GLX002 is a modified new drug based on bosentan dispersible tablets, indicated for pulmonary arterial hypertension (PAH) classified as Group 1 by WHO [1] - The drug aims to improve pulmonary vascular resistance (PVR) in pediatric patients aged 1 year and older with idiopathic or congenital PAH, and to enhance exercise capacity in adult patients with WHO functional classification II to IV PAH [1]